Ipilimumab and radiation in patients with unresectable melanoma brain metastases: A multicenter, open label, phase-2, Spanish Melanoma Group (GEM) study (NCT-2013-001132-22).

Jose A. Lopez-Martin,Ana Arance,Luis de la Cruz-Merino,Ana Illescas,Izazkun Valduvieco,Alfonso Berrocal,José López Torrecilla,Ivan Marquez Rodas,María Teresa Curiel García,Virtudes Soriano,Ana Alvarez,M.L. Chust Vicente,Delvys Rodriguez Abreu,M.C. Peñas Sanchez,Eva Muñoz-Couselo,Javier Aristu,Antonio Gómez Caamaño,Salvador Martin Algarra

Ipilimumab and radiation in patients with unresectable melanoma brain metastases: A multicenter, open label, phase-2, Spanish Melanoma Group (GEM) study (NCT-2013-001132-22).

2018

Jose A. Lopez-Martin
Ana Arance
Luis de la Cruz-Merino
Ana Illescas
Izazkun Valduvieco
Alfonso Berrocal
José López Torrecilla
Ivan Marquez Rodas
María Teresa Curiel García
Virtudes Soriano
Ana Alvarez
M.L. Chust Vicente
Delvys Rodriguez Abreu
M.C. Peñas Sanchez
Eva Muñoz-Couselo
Javier Aristu
Antonio Gómez Caamaño
Salvador Martin Algarra

9546Background: Laboratory and clinical experiences suggest that radiotherapy may be synergistic with anti-CTLA-4 strategies. This hypothesis is explored in melanoma patients (pts) with brain metas...

Keywords:

Ipilimumab
Melanoma
Radiation
Cancer research
Pathology
Medicine
open label
Oncology
in patient
Internal medicine
Radiation therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations